COX-2 inhibitors and their role in gynecology

Obstetrical and Gynecological Survey

Volumn 57, Issue 11, 2002, Pages 768-780

  Hayes, Ellen C ^a,c   Rock, John A ^b  

^a Fellow Repro Endocrin/Infertil   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; 5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; FOLLITROPIN; HYDROCODONE BITARTRATE PLUS PARACETAMOL; IBUPROFEN; INDOMETACIN; KETOPROFEN; LUTEINIZING HORMONE; MELOXICAM; MESTRANOL PLUS NORETHISTERONE; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PIROXICAM; PROGESTERONE; PROSTACYCLIN; PROSTAGLANDIN; ROFECOXIB; THROMBOXANE; UNINDEXED DRUG; UTERUS SPASMOLYTIC AGENT; VALDECOXIB; VASCULOTROPIN;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARACHIDONIC ACID METABOLISM; BRAIN HEMORRHAGE; CARCINOGENESIS; CHILDBIRTH; CLINICAL TRIAL; DRUG EFFICACY; DYSMENORRHEA; ENDOMETRIOSIS; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; GYNECOLOGIC CANCER; HUMAN; INFERTILITY; MENORRHAGIA; MENSTRUAL CYCLE; NECROTIZING ENTERITIS; NEPHROTOXICITY; NONHUMAN; OVARY POLYCYSTIC DISEASE; OVULATION; PAIN; POSTOPERATIVE PAIN; PREECLAMPSIA; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; REVIEW;

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DRUG ADMINISTRATION SCHEDULE; DYSMENORRHEA; ENDOMETRIOSIS; FEMALE; GENITAL DISEASES, FEMALE; HUMANS; INFERTILITY, FEMALE; ISOENZYMES; ISOXAZOLES; LABOR, OBSTETRIC; MEMBRANE PROTEINS; MENORRHAGIA; MENSTRUAL CYCLE; OVARY; OVULATION; PAIN; POLYCYSTIC OVARY SYNDROME; PREGNANCY; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; SULFONAMIDES;

EID: 0036855717     PISSN: 00297828     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006254-200211000-00023     Document Type: Review

References (126)

1. O'Banion MK, Sadowski HB, Winn V et al. A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J Biol Chem 1991;266:23261- 23267.
2. Picot D, Loll PJ, Garavito RM. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 1994;367:243-249.
3. Kurumbail RG, Stevens AM, Gierse JK et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996;384:644-648.
4. Schmassmann A, Peskar BM, Stettler C et al. Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastrointestinal ulcer models in rats. Br J Pharmacol 1998;123:795-804.
5. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998;38:97-120
6. Fosslien E. Adverse effects of nonsteroidal anti-inflammatory drugs on the gastrointestinal system. Ann Clin Lab Sci 1998; 28:67-81.
7. Ehrich EW, Dallob A, De Lepeleire I et al. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther 1999;65:336-347.
8. Fort J. Celecoxib, a COX-2-specific inhibitor. The clinical data. Am J Orthoped 1999;28:13-18.
9. Malmstrom K, Deniels S, Kotey P et al. Comparison of Rofecoxib and Celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: A randomized placebo- and active-comparator-controlled clinical trial. Clin Ther 1999;21: 1653-1663.
10. Morrison BW, Christensen S, Yuan W et al. Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: A randomized, controlled trial. Clin Ther 1999a;21:943-953.
11. Gimbel JS, Brugger A, Zhao W et al. Efficacy and tolerability of celecoxib versus hydrocodone/acetaminophen in the treatment of pain after ambulatory orthopedic surgery in adults. Clin Ther 2001;23:228-41.
12. Emery P, Zeidler H, Kvien TK et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: Randomised double-blind comparison. Lancet 1999;354:2106-2111.
13. Simon LS, Weaver AL, Graham DY et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial. JAMA 1999;282: 1921-1928.
14. Bensen WG, Fiechtner JJ, McMillen JI et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: A randomized controlled trial. Mayo Clin Proc 1999;74:1095-1105.
15. McKenna F, Borenstein D, Wendt H et al. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand J Rheum 2001;30:11-18.
16. Kivitz AJ, Moskowitz RW, Woods E et al. Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip. J Int Med Res 2001b;29:467-479.
17. Goldstein JL, Silverstein FE, Agrawal NM et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000;95:1681-1690.
18. Silverstein FE, Faich G, Golstein JL et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: A randomized controlled trial. JAMA 2000;284:1247-1255.
19. Bensen WG, Zhao SZ, Burke TA et al. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. J Rheumatol 2000;27:1876-1883.
20. Matsumoto H, Ma W, Smalley W et al. Diversification of cyclooxygenase-2-derived prostaglandins in ovulation and implantation. Biol Reprod 2001b;64:1557-1565.
21. Norman RJ. Reproductive consequences of COX-2 inhibition. Lancet 2001;358:1287-1288.
22. Van Voorhis BJ, Huettner PC, Clark MR et al. Immunohistochemical localization of prostaglandin H synthase in the female reproductive tract and endometriosis. Am J Obstet Gynecol 1990;163(1 Pt 1):57-62.
23. Jones RL, Kelly RW, Critchley HO. Chemokine and cyclooxygenase-2 expression in human endometrium coincides with leukocyte accumulation. Hum Reprod 1997;12:1300-1306.
24. Kim JJ, Wang J, Bambra C et al. Expression of cyclooxygenase-1 and -2 in the baboon endometrium during the menstrual cycle and pregnancy. Endocrinology 1999;140: 2672-2678.
25. Tokuyama O, Nakamura Y, Muso A et al. Expression and distribution of cyclooxygenase-2 in human periovulatory ovary. Int J Mol Med 2001;8:603-606.
26. Bieglmayer C, Hofer G, Kainz C et al. Concentrations of various arachidonic acid metabolites in menstrual fluid are associated with menstrual pain and are influenced by hormonal contraceptives. Gynecol Endocrinol 1995;9:307-312.
27. Dawood MY. Nonsteroidal anti-inflammatory drugs and changing attitudes toward dysmenorrhea. Am J Med 1988; 84:23-29.
28. Mehlisch DR, Fulmer RI. A crossover comparison of bromfenac sodium, naproxen sodium, and placebo for relief of pain from primary dysmenorrhea. J Womens Health 1997;6: 83-92.
29. Lindsey K, Jager AK, Raidoo DM et al. Screening of plants used by Southern African traditional healers in the treatment of dysmenorrhoea for prostaglandin-synthesis inhibitors and uterine relaxing activity. J Ethnopharmacol 1999;64:9-14.
30. Ylikorkala O. Prostaglandin synthesis inhibitors in menorrhagia, intrauterine contraceptive device-induced side effects and endometriosis. Pharmacol Toxicol 1994;75 Suppl 2:86-88.
31. Marchini M, Tozzi L, Bakshi R et al. Comparative efficacy of diclofenac dispersible 50 mg and ibuprofen 400 mg in patients with primary dysmenorrhea. A randomized, double-blind, within-patient, placebo-controlled study. Int J Clin Pharmacol Ther 1995;33:491-497.
32. Ezcurdia M, Cortejoso FJ, Lanzon R et al. Comparison of the efficacy and tolerability of dexketoprofen and ketoprofen in the treatment of primary dysmenorrhea. J Clin Pharmacol 1998;38(12 Suppl):65S-73S.
33. Cronberg S, Wallmark E, Söderberg I. Effect on platelet aggregation of oral administration of 10 nonsteroidal analgesics to humans. Scan J Haematol 1984;33:155-159.
34. Leese PT, Hubbard RC, Karim A, Isakson PC, Yu SS, Geis GS. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: A randomized, controlled trial. J Clin Pharmacol 2000;40:124-132.
35. 2 and interleukin-1 beta. Endocrinology 1999;140:2685-2695.
36. Lim H, Paria BC, Das SK et al. Multiple female reproductive failures in cyclooxygenase 2-deficient mice. Cell 1997;91: 197-208.
37. Reese J, Zhao X, Ma WG et al. Comparative analysis of pharmacologic and/or genetic disruption of cyclooxygenase-1 and cyclooxygenase-2 function in female reproduction in mice. Endocrinology 2001;142:3198-3206.
38. Baird DT, Cameron ST, Critchley HO et al. Prostaglandins and menstruation. Eur J Obstet Gynecol Reprod Biol 1996; 70:15-17.
39. Smith G, Roberts R, Hall C et al. Reversible ovulatory failure associated with the development of luteinized unruptured follicles in women with inflammatory arthritis taking nonsteroidal anti-inflammatory drugs. Br J Rheumatol 1996;35: 458-462.
40. 2 in the endometrium throughout the human menstrual cycle, after the administration of clomiphene or an oestrogen-progestogen pill and in early pregnancy. J Endocrinol 1978;77:361-371.
41. Charpigny G, Reinaud P, Tamby JP et al. Cyclooxygenase-2 unlike cyclooxygenase-1 is highly expressed in ovine embryos during the implantation period. Biol Reprod 1997;57: 1032-1040.
42. Marions L, Danielsson KG. Expression of cyclo-oxygenase in human endometrium during the implantation period. Mol Hum Reprod 1999;5:961-965.
43. Scherle PA, Ma W, Lim H et al. Regulation of cyclooxygenase-2 induction in the mouse uterus during decidualization. An event of early pregnancy. J Biol Chem 2000;275:37086-37092.
44. Critchley HO, Jones RL, Lea RG et al. Role of inflammatory mediators in human endometrium during progesterone withdrawal and early pregnancy. J Clin Endocrinol Metab 1999; 84:240-248.
45. Zuo J, Lei ZM, Rao CV et al. Differential cyclooxygenase-1 and -2 gene expression in human myometria from preterm and term deliveries. J Clin Endocrinol Metab 1994;79:894-899.
46. Slater DM, Dennes WJ, Campa JS et al. Expression of cyclooxygenase types-1 and -2 in human myometrium throughout pregnancy. Mol Hum Reprod 1999a;5:880-884.
47. Slater D, Dennes W, Sawdy R et al. Expression of cyclooxygenase types-1 and -2 in human fetal membranes throughout pregnancy. J Mol Endocrinol 1999b;22:125-130.
48. Slater D, Allport V, Bennett P. Changes in the expression of the type-2 but not the type-1 cyclo-oxygenase enzyme in chorion-decidua with the onset of labour. Br J Obstet Gynaecol 1998;105:745-748.
49. Habermehl DA, Janowiak MA, Vagnoni KE et al. Endothelial vasodilator production by uterine and systemic arteries. IV. Cyclooxygenase isoform expression during the ovarian cycle and pregnancy in sheep. Biol Reprod 2000;62:781-788.
50. Akarasereenont P, Techatraisak K, Chotewuttakorn S et al. The expression of cyclooxygenase-2 in human umbilical vein endothelial cell culture from pre-eclampsia. J Med Assoc Thai 1999;82:167-172.
51. Wetzka B, Nusing R, Charnock-Jones DS et al. Cyclooxygenase-1 and -2 in human placenta and placental bed after normal and pre-eclamptic pregnancies. Hum Reprod 1997; 12:2313-2320.
52. Reese J, Paria BC, Brown N et al. Coordinated regulation of fetal and maternal prostaglandins directs successful birth and postnatal adaptation in the mouse. Proc Natl Acad Sci USA 2000;97:9759-9764.
53. O'Brien WF. The role of prostaglandins in labor and delivery. Clin Perinatol 1995;22:973-984.
54. Olson DM, Mijovic JE, Sadowsky DW. Control of human parturition. Semin Perinatol 1995;19:52-63.
55. Gibb W. The role of prostaglandins in human parturition. Ann Med 1998;30:235-241.
56. Dong YL, Gangula PR, Fang L et al. Differential expression of cyclooxygenase-1 and -2 proteins in rat uterus and cervix during the estrous cycle, pregnancy, labor and in myometrial cells. Prostaglandins 1996;52:13-34.
57. Challis JR, Lye SJ, Gibb W. Prostaglandins and parturition. Ann N Y Acad Sci 1997;828:254-267.
58. Fuentes A, Spaziani EP, O'Brien WF. The expression of cyclooxygenase-2 (COX-2) in amnion and decidua following spontaneous labor. Prostaglandins 1996;52:261-267.
59. Sawdy RJ, Slater DM, Dennes WJ et al. The roles of the cyclo-oxygenases types one and two in prostaglandin synthesis in human fetal membranes at term. Placenta 2000;21: 54-57.
60. Kniss DA, Zimmerman PD, Gabbe SG et al. Selective ablation of cyclooxygenase-2 gene expression and prostaglandin biosynthesis by antisense phosphorothioates. J Soc Gynecol Invest 1996;(3 Suppl):95A.
61. Besinger RE, Niebyl JR, Keyes WG et al. Randomized comparative trial of indomethacin and ritodrine for the long-term treatment of preterm labor. Am J Obstet Gynecol 1991;164: 981-986.
62. Kurki T, Eronen M, Lumme R et al. A randomized double-dummy comparison between indomethacin and nylidrin in threatened preterm labor. Obstet Gynecol 1991;78:1093-1097.
63. Slattery MM, Friel AM, Healy DG et al. Uterine relaxant effects of cyclooxygenase-2 inhibitors in vitro. Obstet Gynecol 2001;98:563-569.
64. Kniss DA. Cyclooxygenases in reproductive medicine and biology. J Soc Gyn Invest 1999;6:285-292.
65. Zuckerman H, Shalev E, Gilad G et al. Further study of the inhibition of premature labor by indomethacin. Part I. J Perinat Med 1984;12:19-23.
66. Moise, KJJ, Huhta JC, Sharif DS et al. Indomethacin in the treatment of preterm labor: Effects on the fetal ductus arteriosus. N Engl J Med 1988;319:327-331.
67. Norton ME, Merrill J, Cooper BA et al. Neonatal complications after the administration of indomethacin for preterm labor. N Engl J Med 1993;329:1602-1607.
68. Vermillion ST, Landen CN. Prostaglandin inhibitors as tocolytic agents. Semin Perinatol 2001;25:256-262.
69. Guerguerian AM, Hardy P, Bhattacharya M et al. Expression of cyclooxygenases in ductus arteriosus of fetal and newbom pigs. Am J Obstet Gynecol 1998;179(6 Pt 1):1618-1626.
70. Loftin CD, Trivedi DB, Tiano HF et al. Failure of ductus arteriosus closure and remodeling in neonatal mice deficient in cyclooxygenase-1 and cyclooxygenase-2. Proc Natl Acad Sci USA 2001;98:1059-1064.
71. Manchester D, Margolis HS, Sheldon RE. Possible association between maternal indomethacin therapy and primary pulmonary hypertension of the newborn. Am J Obstet Gynecol 1967;126:467-471.
72. Eronen M, Pesonen E, Kurki T et al. The effects of indomethacin and a beta-sympathomimetic agent on the fetal ductus arteriosus during treatment of premature labor: A randomized double-blind study. Am J Obstet Gynecol 1991;164: 141-146.
73. Anderson RJ, Berl T, McDonald KD et al. Evidence for an in vivo antagonism between vasopressin and prostaglandin in the mammalian kidney. J Clin Invest 1975;56:420-426.
74. Dinchuk JE, Car BD, Focht RJ et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 1995;378:406-409.
75. Morham SG, Langenbach R, Loftin CD et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 1995;83:473-482.
76. Hawkey CJ. COX-2 inhibitors. Lancet 1999;353:307-314.
77. Sakai M, Tanebe K, Sasaki Y et al. Evaluation of the tocolytic effect of a selective cyclooxygenase-2 inhibitor in a mouse model of lipopolysaccharide-induced preterm delivery. Mol Hum Reprod 2001;7:595-602
78. Gross G, Imamura T, Vogt SK et al. Inhibition of cyclooxygenase prevents inflammation-mediated preterm labor in the mouse. Am J Physiol Regul Integr Comp Physiol 2000;278: R1415-23.
79. Ota H, Igarashi S, Sasaki M et al. Distribution of cyclooxygenase-2 in eutopic and ectopic endometrium in endometriosis and adenomyosis. Hum Reprod 2001;16:561-566.
80. Deguchi M, Ishiko O, Sumi T et al. Expression of angiogenic factors in extrapelvic endometriosis. Oncol Rep 2001;8: 1317-1319.
81. 2alpha release by human peritoneal macrophages in endometriosis. Prostaglandins 1996;51:49-60
82. 2 release. Obstet Gynecol 1998;91:25-29.
83. Koike H, Egawa H, Ohtsuka T et al. Correlation between dysmenorrheic severity and prostaglandin production in women with endometriosis. Prostaglandins Leukot Essent Fatty Acids 1992;46:133-137.
84. Olive DL, Pritts EA. Treatment of endometriosis. N Engl J Med 2001;345:266-275.
85. Guvenal T, Cetin A, Ozdemir H et al. Prevention of postoperative adhesion formation in rat uterine horn model by nimesulide: A selective COX-2 inhibitor. Hum Reprod 2001;16: 1732-1735.
86. 2 by human granulosa cells from polycystic ovaries. Prostaglandins 1996;52:187-197.
87. Akil M, Amos RS, Stewart P. Infertility may sometimes be associated with NSAID consumption. Br J Rheumatol 1996; 35:76-78.
88. Mendonca LL, Khamashta MA, Nelson-Piercy C et al. Nonsteroidal anti-inflammatory drugs as a possible cause for reversible infertility. Rheumatology (Oxford) 2000;39:880-882.
89. Pall M, Fridén BE, Brännström M. Induction of delayed follicular rupture in the human by the selective COX-2 inhibitor rofecoxib: A randomized double-blind study. Hum Reprod 2001;16:1323-1328.
90. Talley JJ, Brown DL, Carter JS et al. 4-[5-Methyl-3-phenylisoxazol-4-yl]-benzenesulfonamide, valdecoxib: A potent and selective inhibitor of COX-2. J Med Chem 2000; 43:775-777.
91. Bensen W, Weaver A, Espinoza L et al. Valdecoxib, a new COX-2 specific inhibitor, is effective in treating the signs and symptoms of rheumatoid arthritis. Arthritis Rheum 2001; 44(Suppl):Abstract 1896.
92. Goldstein JL, Zhao WW, Kent JD et al. Reduced incidence of gastroduodenal ulcers with valdecoxib, a potent COX-2 specific inhibitor, compared to ibuprofen and diclofenac in patients with osteoarthritis: A multicenter trial. Gastroenterology 2001;120(Suppl 1).
93. Kivitz A, Eisen G, Zhao WW et al. The COX-2 specific inhibitor valdecoxib is as effective as the conventional NSAID naproxen in treating symptomatic osteoarthritis of the knee and demonstrates reduced gastrointestinal ulceration. Arthritis Rheum 2001a;(Suppl)44:Abstract 500.
94. Hersch E, Moore P, Ross G. Over-the-counter analgesics and antipyretics: A critical assessment. Clin Ther 2000;22: 500-548.
95. Deleted in proof.
96. Morrison BW, Daniels SE, Kotey P et al. Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: A randomized controlled trial. Obstet Gynecol 1999b;94:504-508.
97. Masferrer J. Approach to angiogenesis inhibition based on cyclooxygenase-2. Cancer J 2001;(7 Suppl 3):S144-S150.
98. Marnett LJ. Generation of mutagens during arachidonic acid metabolism. Cancer Metastasis Rev 1994;13:303-308.
99. Marnett LJ. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 1992;52:5575-5580.
100. Masferrer JL, Leahy KM, Koki AT et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306-1311.
101. Eberhart CE, Coffey RJ, Radhika A et al. Up-regulation of cyclo-oxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107:1183-1188.
102. Leahy KM, Ornberg RL, Wang Y et al. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 2002;62:625-631.
103. Ryu HS, Chang KH, Yang HW et al. High cyclooxygenase-2 expression in stage IB cervical cancer with lymph node metastasis or parametrial invasion. Gynecol Oncol 2000;76: 320-325.
104. Formenti S, Felix J, Salonga D et al. Expression of metastases-associated genes in cervical cancers resected in the proliferative and secretory phases of the menstrual cycle. Clin Cancer Res 2000;6:4653-4657.
105. Gaffney DK, Holden J, Davis M et al. Elevated cyclooxygenase-2 expression correlates with diminished survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys 2001a;49:1213-1217.
106. Gaffney DK, Holden J, Zempolich K et al. Elevated COX-2 expression in cervical carcinoma: Reduced cause-specific survival and pelvic control. Am J Clin Oncol 2001b;24:443-446.
107. Ishiko O, Sumi T, Yoshida H et al. Association between overexpression of cyclooxygenase-2 and suppression of apoptosis in advanced cancer of the uterine cervix after cyclic balloon -occluded arterial infusion. Oncol Rep 2001;8:1259-1263.
108. Matsumoto Y, Ishiko O, Deguchi M et al. Cyclooxygenase-2 expression in normal ovaries and epithelial ovarian neoplasms. Int J Mol Med 2001a;8:31-36.
109. Sumi T, Ishiko O, Yoshida H et al. Expression of cyclooxygenase-2 in ovarian mature cystic teratomas with malignant transformation. Int J Mol Med 2001;8:495-8.
110. Subbaramaiah K, Norton L, Gerald W et al. Cyclooxygenase-2 is overexpressed in her-2/neu-positive breast cancer. Evidence for involvement of AP-1 and PEA3. J Biol Chem 2002.
111. Liu CH, Chang SH, Narko K et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001;276:18563-18569.
112. Ristimaki A, Sivula A, Lundin J et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002;62:632-635.
113. Brodie AM, Lu Q, Long BJ et al. Aromatase and COX-2 expression in human breast cancers. J Steroid Biochem Mol Biol 2001;79:41-47.
114. Cotterchio M, Kreiger N, Sloan M et al. Nonsteroidal anti-inflammatory drug use and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2001;10:1213-1217.
115. Rozic JG, Chakraborty C, Lala PK. Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. Int J Cancer 2001;93:497-506.
116. Alshafie GA, Abou-Issa HM, Seibert K et al. Chemotherapeutic evaluation of Celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model. Oncol Rep 2000;7:1377-1381.
117. Abou-Issa HM, Alshafie GA, Seibert K et al. Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis. Anticancer Res 2001; 21:3425-3432.
118. Gabriel SE, Bombardier C. NSAID-induced ulcers. An emerging epidemic? J Rheumatol 1990;17:1-4.
119. Hayllar J, Bjarnason I. Gastroduodenal tolerability of highly specific cyclo-oxygenase-1 inhibitor. Ital J Gastroenterol 1996;28:30-32.
120. Lichtenstein DR, Syngal S, Wolfe MM. Nonsteroidal anti-inflammatory drugs and the gastrointestinal tract: The double-edged sword. Arthritis Rheum 1995;38:5-18.
121. White WB, Faich G, Whelton A et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 2002;89:425-430.
122. Whelton A, Schulman G, Wallemark C et al. Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med 2000a;160:1465-1470.
123. Whelton A. Cyclooxygenase-2 inhibition and renal function. Ann Intern Med 2001;134:1077-107.
124. Whelton A. Renal and related cardiovascular effects of conventional and COX-2-specific NSAIDs and non-NSAID analgesics. Am J Ther 2000b;7:63-74.
125. Zhao SZ, Reynolds MW, Lejkowith J et al. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database. Clin Ther 2001;23:1478-1491.
126. Schwartz JI, Wong PH, Porras AG et al. Effect of rofecoxib on the pharmacokinetics of chronically administered oral contraceptives in healthy female volunteers. J Clin Pharmacol 2002;42:215-221.